What are the recommended medications and dosing for managing hyperuricemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications for Hyperuricemia

For patients with gout, start allopurinol at a low dose (≤100 mg/day, even lower if CKD stage ≥3) and titrate upward every 2-4 weeks to reach a serum urate target of <6 mg/dL (<5 mg/dL for severe gout with tophi). 1

Key Principle: Treat Gout, Not Asymptomatic Hyperuricemia

Do not initiate urate-lowering therapy (ULT) for asymptomatic hyperuricemia (serum urate >6.8 mg/dL without prior gout flares or tophi). The number needed to treat is 24 patients for 3 years to prevent a single gout flare, making the risks and costs outweigh benefits for most patients. 1

First-Line Medication: Allopurinol

Allopurinol is the strongly recommended first-line agent for all patients with gout, including those with moderate-to-severe chronic kidney disease (CKD stage ≥3). 1, 2

Allopurinol Dosing Strategy:

  • Starting dose: ≤100 mg/day (≤50 mg/day in CKD stage ≥3)
  • Titration: Increase by 100 mg increments every 2-4 weeks
  • Maximum dose: Up to 800 mg/day (FDA-approved maximum)
  • Target: Serum urate <6 mg/dL (or <5 mg/dL for severe gout with tophi, chronic arthropathy, or frequent attacks) 1, 2

The low starting dose mitigates the risk of allopurinol hypersensitivity syndrome and reduces flare risk during ULT initiation. 1

Second-Line Options

Febuxostat

  • Use when: Allopurinol target not achieved at maximum dose, or allopurinol not tolerated
  • Starting dose: ≤40 mg/day with subsequent titration
  • Advantage: Can be used in moderate-to-severe CKD (preferred over probenecid in CKD stage ≥3) 1, 2
  • Note: Recent Chinese guidelines suggest febuxostat as first-line for asymptomatic hyperuricemia in specific populations, though this contradicts ACR/EULAR recommendations 3

Probenecid (Uricosuric)

  • Starting dose: 500 mg once to twice daily with titration
  • Contraindication: Moderate-to-severe CKD (stage ≥3) - use allopurinol or febuxostat instead 1
  • Use when: Normal kidney function and allopurinol/febuxostat not tolerated or ineffective

Combination Therapy

If serum urate target cannot be reached with allopurinol alone at appropriate doses, either:

  • Switch to febuxostat, OR
  • Switch to a uricosuric, OR
  • Combine allopurinol with a uricosuric 2

Third-Line: Pegloticase

Strongly recommended AGAINST as first-line therapy. 1

Reserved exclusively for crystal-proven severe debilitating chronic tophaceous gout with poor quality of life when serum urate target cannot be reached with any other available drug at maximal dosage (including combinations). 2

Essential Flare Prophylaxis

All patients starting ULT must receive prophylaxis for the first 6 months to prevent gout flares triggered by crystal dissolution:

  • First choice: Colchicine 0.5-1 mg/day (reduce dose in renal impairment)
  • Alternative: Low-dose NSAIDs if colchicine contraindicated or not tolerated 2

Critical caveat: Avoid co-prescribing colchicine with strong P-glycoprotein or CYP3A4 inhibitors due to neurotoxicity/muscular toxicity risk, especially in patients with renal impairment or on statins. 2

Monitoring and Maintenance

  • Target serum urate: <6 mg/dL for all patients; <5 mg/dL for severe gout until crystal dissolution
  • Avoid: Long-term serum urate <3 mg/dL 2
  • Duration: Lifelong maintenance once target achieved 2

Special Populations

Chronic Kidney Disease

  • Adjust allopurinol maximum dose to creatinine clearance
  • If target not achieved, switch to febuxostat or benzbromarone (except if eGFR <30 mL/min) 2
  • Both allopurinol and febuxostat are preferred over probenecid in CKD stage ≥3 1

Young Patients or High-Risk Features

Consider ULT initiation early (close to first diagnosis) in patients:

  • Age <40 years at gout onset
  • Serum urate >8.0 mg/dL (480 μmol/L)
  • Comorbidities: renal impairment, hypertension, ischemic heart disease, heart failure 2

Common Pitfalls to Avoid

  1. Starting at high doses: Always start low and titrate to avoid triggering flares and hypersensitivity reactions
  2. Treating asymptomatic hyperuricemia: No mortality/morbidity benefit demonstrated; avoid unnecessary treatment
  3. Inadequate prophylaxis: Failure to provide 6 months of flare prophylaxis leads to poor adherence
  4. Stopping at 300 mg allopurinol: Many patients require >300 mg/day to reach target; titrate up to 800 mg if needed 1
  5. Using probenecid in CKD: Ineffective and potentially harmful in moderate-to-severe renal impairment

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.